Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 04 04:00PM ET
47.25
Dollar change
-1.94
Percentage change
-3.94
%
Index- P/E- EPS (ttm)-3.23 Insider Own41.81% Shs Outstand30.50M Perf Week-8.25%
Market Cap1.44B Forward P/E- EPS next Y-1.15 Insider Trans4.74% Shs Float17.75M Perf Month0.70%
Income-33.18M PEG- EPS next Q-0.27 Inst Own63.48% Short Float8.53% Perf Quarter58.77%
Sales0.00M P/S- EPS this Y13.94% Inst Trans-1.05% Short Ratio4.74 Perf Half Y866.26%
Book/sh1.50 P/B31.47 EPS next Y53.58% ROA-69.46% Short Interest1.51M Perf Year1990.71%
Cash/sh1.72 P/C27.48 EPS next 5Y15.00% ROE-172.71% 52W Range1.94 - 53.82 Perf YTD17.39%
Dividend Est.- P/FCF- EPS past 5Y35.36% ROI-141.58% 52W High-12.21% Beta-1.53
Dividend TTM- Quick Ratio1.85 Sales past 5Y0.00% Gross Margin- 52W Low2335.57% ATR (14)2.51
Dividend Ex-Date- Current Ratio1.85 EPS Y/Y TTM-0.82% Oper. Margin0.00% RSI (14)49.37 Volatility6.11% 5.32%
Employees32 Debt/Eq0.02 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price63.17
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-25.34% Payout- Rel Volume0.99 Prev Close49.19
Sales Surprise- EPS Surprise-64.73% Sales Q/Q- EarningsNov 07 BMO Avg Volume319.25K Price47.25
SMA20-2.26% SMA505.72% SMA200121.71% Trades Volume317,035 Change-3.94%
Date Action Analyst Rating Change Price Target Change
Feb-05-24Initiated Piper Sandler Overweight $93
Jan-23-24Initiated Stifel Buy $63
Nov-21-23Resumed Guggenheim Buy $40
Sep-29-20Initiated Guggenheim Buy $8
Jan-10-20Initiated Craig Hallum Buy $8
Dec-23-19Initiated Oppenheimer Outperform $10
Feb-13-18Reiterated Maxim Group Buy $8 → $4
Feb-22-24 08:00AM
Feb-14-24 08:50AM
Feb-05-24 10:10AM
Feb-01-24 08:00AM
Jan-29-24 04:05PM
08:50AM Loading…
Jan-26-24 08:50AM
Jan-24-24 08:00AM
Jan-10-24 08:50AM
Jan-05-24 08:00AM
Dec-21-23 06:59PM
Dec-15-23 09:30AM
Dec-14-23 03:44PM
03:05PM
07:00AM
Dec-01-23 03:06AM
01:02PM Loading…
Nov-27-23 01:02PM
Nov-20-23 03:06PM
Nov-10-23 04:05PM
Nov-07-23 08:00AM
Nov-06-23 08:00AM
Nov-01-23 11:30AM
Oct-26-23 10:33AM
Oct-20-23 01:22PM
Oct-16-23 04:07PM
08:01AM
Oct-06-23 06:25PM
Oct-04-23 06:16PM
04:05PM
Oct-03-23 08:00AM
Oct-02-23 04:05PM
09:58AM Loading…
Sep-28-23 09:58AM
08:30AM
Sep-27-23 06:08PM
04:55PM
04:01PM
03:30PM
01:28PM
07:21AM
Sep-26-23 04:11PM
12:51PM
12:17PM
07:30AM
Sep-25-23 08:00AM
Aug-18-23 09:02PM
Aug-16-23 08:00AM
Aug-08-23 04:05PM
Jun-02-23 06:35PM
May-09-23 04:05PM
May-03-23 04:05PM
Apr-26-23 06:50AM
Mar-28-23 08:00AM
Mar-21-23 04:05PM
Mar-16-23 06:33AM
Mar-07-23 08:00AM
Feb-01-23 04:25PM
Jan-26-23 08:00AM
Jan-13-23 12:00PM
Dec-19-22 08:00AM
Nov-09-22 04:05PM
Oct-10-22 11:23AM
Oct-03-22 08:00AM
Sep-30-22 11:47AM
Sep-29-22 11:42AM
Sep-22-22 10:57AM
Sep-20-22 12:04PM
Sep-12-22 11:26AM
Sep-07-22 10:02AM
Sep-06-22 08:00AM
Aug-18-22 11:04AM
Aug-10-22 04:05PM
Jul-20-22 10:59AM
08:00AM
Jul-11-22 04:05PM
Jul-07-22 09:36AM
08:39AM
Jul-06-22 09:32AM
Jun-14-22 05:56AM
Jun-13-22 04:05PM
Jun-07-22 08:00AM
May-19-22 04:05PM
May-17-22 11:53AM
08:00AM
May-12-22 10:20AM
May-11-22 11:20AM
May-10-22 04:01PM
May-06-22 11:11AM
May-05-22 11:26AM
11:07AM
May-02-22 04:05PM
Apr-13-22 03:34PM
Apr-11-22 06:16PM
Apr-01-22 11:49AM
Mar-31-22 04:05PM
Mar-29-22 08:30AM
Mar-28-22 04:01PM
Mar-27-22 01:59PM
Mar-09-22 08:00AM
Feb-08-22 08:00AM
Jan-28-22 04:48PM
Jan-24-22 09:24AM
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anish BhatnagarCHIEF EXECUTIVE OFFICERJan 25Sale48.302,527122,054171,770Jan 29 05:42 PM
Hirano Patricia CSEE REMARKSJan 25Sale48.3083240,18643,142Jan 29 05:44 PM
Yen KristenSEE REMARKSJan 25Sale48.3039719,17525,640Jan 29 05:47 PM
Hirano Patricia CSee RemarksDec 14Sale36.491,35949,58419,974Dec 15 06:00 PM
Yen KristenSee RemarksDec 13Option Exercise2.5517,91645,64419,953Dec 14 07:57 PM
Yen KristenSee RemarksDec 13Sale37.7617,916676,5572,037Dec 14 07:57 PM
Hirano Patricia CSee RemarksDec 13Sale38.794,885189,51321,333Dec 15 06:00 PM
Yen KristenSee RemarksDec 12Sale36.9519,913735,8742,037Dec 14 07:57 PM
Mackaness James HChief Financial OfficerDec 11Option Exercise2.6015,00038,92544,610Dec 13 09:34 PM
Anish BhatnagarChief Executive OfficerDec 11Sale35.6793,4083,331,70124,297Dec 13 09:34 PM
Mackaness James HChief Financial OfficerDec 11Sale36.4132,4821,182,82812,128Dec 13 09:34 PM
Anish BhatnagarChief Executive OfficerNov 30Sale28.6527,716794,116108,062Dec 04 08:02 PM
Mackaness James HChief Financial OfficerNov 30Sale28.654,186119,93721,303Dec 04 08:04 PM
Yen KristenSee RemarksNov 30Sale28.653,963113,54721,950Dec 04 08:06 PM
Hirano Patricia CSee RemarksNov 30Sale28.653,823109,53626,218Dec 04 08:03 PM
Anish BhatnagarChief Executive OfficerNov 29Sale27.8327,827774,535135,778Nov 30 09:50 PM
Mackaness James HChief Financial OfficerNov 29Sale27.834,203116,98625,489Nov 30 09:52 PM
Yen KristenSee RemarksNov 29Sale27.833,979110,75125,913Nov 30 09:52 PM
Hirano Patricia CSee RemarksNov 29Sale27.833,839106,85530,041Nov 30 09:51 PM
Anish BhatnagarChief Executive OfficerNov 28Sale27.1225,678696,514163,605Nov 30 09:50 PM
Mackaness James HChief Financial OfficerNov 28Sale27.123,878105,19029,692Nov 30 09:52 PM
Yen KristenSee RemarksNov 28Sale27.123,67199,57529,892Nov 30 09:52 PM
Hirano Patricia CSee RemarksNov 28Sale27.123,54296,07633,880Nov 30 09:51 PM
Anish BhatnagarChief Executive OfficerOct 20Option Exercise3.169,64330,500198,926Dec 13 09:32 PM
Mackaness James HChief Financial OfficerOct 02Option Exercise2.958,30924,49741,879Dec 13 09:32 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 28Buy20.00250,0005,000,0003,074,542Sep 28 03:45 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 26Buy16.40616,78910,113,9162,824,542Sep 28 03:45 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 06Buy5.932001,1862,207,753Jun 06 04:16 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 05Buy5.9878,468469,2392,207,553Jun 06 04:16 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 02Buy5.9364,630383,2562,129,085Jun 06 04:16 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 01Buy5.597,50041,9252,064,455Jun 01 05:41 PM
PERCEPTIVE ADVISORS LLC10% OwnerMay 31Buy5.2810,00052,8002,056,955Jun 01 05:41 PM
PERCEPTIVE ADVISORS LLC10% OwnerMay 30Buy5.3417,50093,4502,046,955Jun 01 05:41 PM
PERCEPTIVE ADVISORS LLC10% OwnerMay 26Buy5.2722,500118,5752,029,455May 26 05:57 PM
PERCEPTIVE ADVISORS LLC10% OwnerMay 25Buy5.1837,500194,2502,006,955May 26 05:57 PM
PERCEPTIVE ADVISORS LLC10% OwnerMay 24Buy5.4825,000137,0001,969,455May 26 05:57 PM
PERCEPTIVE ADVISORS LLC10% OwnerMay 23Buy5.4527,500149,8751,944,455May 23 06:47 PM
PERCEPTIVE ADVISORS LLC10% OwnerMay 22Buy5.1227,300139,7761,916,955May 23 06:47 PM
PERCEPTIVE ADVISORS LLC10% OwnerMay 19Buy4.6225,200116,4241,889,655May 23 06:47 PM